Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Show more...
FAQ
Catalyst Biosciences 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Stuttgart 交易所,Catalyst Biosciences 的股票以代號 HGF2.STU 進行交易。
Catalyst Biosciences 下一次財報日期是什麼時候?▼
Catalyst Biosciences 將於 November 18, 2026 公布下一次財報。
Catalyst Biosciences 上一季度的財報如何?▼
HGF2.STU 上一季度的財報為每股 -0.1 EUR,預估為 -0.05 EUR,帶來 -111.76% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Catalyst Biosciences 去年的營收是多少?▼
Catalyst Biosciences 去年的營收為 100.84MEUR。
Catalyst Biosciences 去年的淨利是多少?▼
HGF2.STU 去年的淨收益為 4.48MEUR。
Catalyst Biosciences 會發放股息嗎?▼
是的,HGF2.STU 的股息每 每季 發放一次。每股最新股息為 3.32 EUR。截至今日,股息殖利率(FWD)% 為 0%。
Catalyst Biosciences 有多少名員工?▼
截至 September 05, 2026,公司共有 618 名員工。
Catalyst Biosciences 位於哪個產業?▼
Catalyst Biosciences從事於Health & Wellness產業。
Catalyst Biosciences 何時完成拆股?▼
Catalyst Biosciences 上次拆股發生於 October 31, 2023,比例為 1:15。
Catalyst Biosciences 的總部在哪裡?▼
Catalyst Biosciences 的總部位於 美國 的 SAN DIEGO。